Berotralstat (BCX7353) Synthesis and Patent Landscape
The synthesis of berotralstat, also known as BCX7353, is a key area of interest for understanding its development and market exclusivity. Patent information provides insights into the protection surrounding its manufacturing process and the drug itself.
What is Berotralstat's Chemical Structure and How is it Synthesized?
Berotralstat is a small molecule inhibitor of plasma kallikrein. Its synthesis involves a multi-step chemical process. While specific detailed synthetic schemes are often proprietary, the development of such complex molecules typically requires precise control over chemical reactions to ensure purity and yield. Information on the exact synthesis may be found in patents and scientific literature [1].
When Does the Patent for Berotralstat Expire?
The patent protection for berotralstat is crucial for its commercial lifecycle. Patent expiry dates determine when generic versions can potentially enter the market. The primary patent for berotralstat is expected to expire around 2035, although this can be influenced by various factors including patent term extensions and new patent filings [2]. DrugPatentWatch.com tracks these patent expiries and related information [2].
What Other Patents Cover Berotralstat?
Beyond the primary composition of matter patent, there can be other patents covering various aspects of berotralstat. These may include patents related to specific crystalline forms, formulations, methods of use, or manufacturing processes. Such secondary patents can extend market exclusivity beyond the initial patent expiry [2].
What is the Regulatory Status of Berotralstat?
Berotralstat has received regulatory review and approval in certain markets for specific indications. For instance, it is approved in the United States for the prophylactic treatment of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older [1]. Regulatory approvals are a critical step before a drug can be marketed.
What are the Risks and Side Effects Associated with Berotralstat?
As with any medication, berotralstat carries potential risks and side effects. Common side effects reported include upper respiratory tract infection, diarrhea, nausea, abdominal pain, and vomiting [1]. Patients and healthcare providers should be aware of these potential adverse events.
Are There Competitors to Berotralstat for Hereditary Angioedema?
The market for HAE treatments includes other therapies. Berotralstat competes with other approved medications for HAE, which may include different mechanisms of action or delivery methods. The competitive landscape can influence market dynamics and pricing [1].
What is the Price of Berotralstat?
The pricing of berotralstat is a significant consideration for patients and healthcare systems. As a branded medication for a rare disease, its cost can be substantial. Pricing is influenced by factors such as development costs, manufacturing, market demand, and the pricing of competing therapies [1].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214159s005lbl.pdf
2. https://drugpatentwatch.com/